Skip to main content
. 2016 Jan 14;127(15):1870–1880. doi: 10.1182/blood-2015-09-666214

Figure 1.

Figure 1

Type of mutations detected at baseline. Mutations detected before ponatinib initiation (baseline) in 363 patients enrolled in the PACE trial, arranged from the top according to the most frequently detected by Sanger sequencing. Low-level mutations were detected by MS but not by Sanger sequencing, and therefore represent between 0.05% and 10% of the BCR-ABL1 species within the sample.